Concepedia

Publication | Open Access

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

DOIFull Paper Access

277

Citations

33

References

2019

Year

Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes‐Davies, Adrian Harnett, Mei-Lin Ah-See, Richard Simcock, Daniel Rea,
The Lancet

Abstract

UK National Institute for Health Research, Health Technology Assessment Programme.

References

YearCitations

Page 1